www.nature.com/nrrheum News & VIews medicine. notably, the researchers resurfaced not just a focal defect but an entire joint surface, which broadens the technology's application beyond the treatment of sports injuries into the arena of osteoarthritis, a critically large and unmet clinical need. the reliance on the body's own cell population for effecting the regenerative process by cell-homing and recruitment negates the need for complicated exogenouscell-based therapies, effectively providing the clinician with readily available implants in the operating room.
although lee et al. demonstrate how this mechanism of regeneration can be successful in principle, and have thus opened a new paradigm for effecting cartilage regeneration, there remain important unanswered questions that will need to be addressed before this technology can gain widespread clinical acceptance. First, the optimization of growth factor dosage, as well as other synergistic combinations, such as growth factor 'cocktails' capable of further enhancing the quality of the resultant cartilage tissue, need further evaluation. second, the rabbit model, although a good testing ground for proof-ofconcept studies, might not be translatable to models of larger weight-bearing joints or indeed humans. rabbit studies have typically shown excellent short-term results, but a degradative process seems to occur in the 6-12 month range. third, the ideal bio material combination is also a critical compo nent to success. of particular in terest is the actual source of the cells homing to the morphogen-loaded scaffold. it is likely that these cells are emanating from both the subchondral bone marrow as well as the syno genome-wide association studies of human diseases have uncovered large numbers of common genetic variants with small effect sizes; however, rare genetic variants with large effect sizes might have greater relevance with respect to disease heritability. the identification and characterization of rare variants-such as those recently discovered in SIAE-is, therefore, likely to be a major endeavor in the field in the coming years.
Genome-wide association studies (Gwas) have identified >2,000 common genetic variants associated with various human diseases. 1 However, these common genetic variants confer small effect sizes, as measured by their estimated odds ratios, and collectively account for only a modest fraction of total disease heritability. this is certainly true of the Gwas-elucidated genes in rheumatic autoimmune diseases.
2,3 By contrast, rare genetic variants can exhibit consider ably larger effect sizes than common genetic variants, and might have a more direct and profound impact on disease pathogenesis. it also seems likely that these rare genetic variants, particularly if highly penetrant, might be more pre dic tive of disease than commonly occurring re gulatory variants. a study by surolia et al. 4 has identified SIAE as the latest addition to the class of autoimmunity genes with rare variants, a list that includes TREX1 and IFIH1. SIAE, which encodes sialate O-acetylesterase, has an autoimmunity-associated odds ratio >8, clearly dwarfing the odds ratios associated with autoimmunity genes previously identified by Gwas. 2, 3 sialate O-acetylesterase deacetylates sialic acid at the 9-oH position and promotes the binding of sialic acids to CD22, a negative regulator of B-cell receptor signaling. the subsequent phosphoryla tion of CD22 by the tyrosine-protein kinase lyn is followed by the recruitment and activation of tyrosine-protein phosphatase non-receptor type 6 (also known as sHP-1). these effects ultimately dampen calcium flux induced by the B-cell receptor, with important consequences for B-cell tolerance. 5, 6 indeed, mice with mutations in components of this pathway develop lupus-like autoimmunity. [5] [6] [7] [8] Collectively, these observations underline the obligatory role of this molecular pathway in regulating humoral immune responses and preventing humoral autoimmunity.
the role of sialate O-acetylesterase and its associated molecular cascade in autoimmune diseases other than systemic lupus erythemato sus is unclear and warrants further study. rare loss-of-function SIAE variants were predominantly associated with rheumatoid arthritis and type 1 diabetes. 4 the fact that cell-surface expression of 9-Oacetyl sialic acid is increased on activated B cells from patients with defective SIAE variants 4 suggests that sialate O-acetylesterase can also act in a B-cell-intrinsic manner in other auto immune diseases. B-cell depletion therapy is effective in several auto immune nature reviews | rheumatology volume 6 | DeCemBer 2010 | 679
News & VIews disorders, under scoring the potential pathogenic role of B cells in these diseases. sialate O-acetylesterase activity has the potential to modulate the threshold for B-cell tolerance and shape the antibody repertoire. 5 it is conceivable, therefore, that loss-offunction variants of SIAE might have a role in the emergence of specific autoantibody subsets associated with rheumatoid arthritis or type 1 diabetes; however, this hypothesis needs experimental verification. an alternative, but not mutually exclusive, interpretation of the findings of surolia et al. 4 is that sialate O-acetylesterase limits auto immunity through a specific action on non-B-cells. several patients with an autoimmune disease, but not the healthy controls, were homozygous for a SIAE variant that encodes a catalytically-active protein that is unable to be secreted. 4 this observation supports a cell-extrinsic role for sialate O-acetylesterase in auto immunity. it will be interesting, therefore, to explore the consequences of SIAE mutations on the activation and function of other immune cells.
the work by suolia et al. 4 has important ramifications on several fronts. it is a clear signal that we should move beyond Gwas, and solely the identification of common genetic variants, towards elucidating the effect that rare genetic variants might have on various autoimmune disorders (Box 1). indeed, this effort is likely to dominate the field in the coming years, given the potential of next-generation sequencing.
9 these findings might also affect how we interpret the importance to human disease of genes that are identified in mouse models. even if a gene fails to emerge as being diseaseassociated in Gwas, the possibility that rare variants of the gene might contribute to human disease must be borne in mind. it is also noteworthy that the approach to identify common genetic variants using Gwas might also guide us towards the rare disease-causative variants that have large effect sizes. indeed, the resequenc ing of Gwas-elucidated genes with small effect sizes for hyper triglyceridemia led to the identification of >150 rare genetic variants with larger effect sizes. 10 as an increasing number of rare genetic variants are deposit ed in the database of auto immunity genes (which, at present, are largely populated with Gwaselucidated genes), the hope is that we will eventually be in a position to account for all of the heritability of autoimmunity.
it is intriguing how some genes, such as SIAE, have sizeable effects on multiple autoimmune diseases. although the cellular and molecular mechanisms that might be altered in each disease setting need to be carefully dissected, these findings suggest that a subset of genes might be operating across multiple autoimmune diseases, perhaps by infringing on key checkpoints in immune tolerance to self-antigens. whether SIAE also affects other systemic or end-organ mechanisms leading to autoimmunity remains to be investigated. our understanding of the molecular basis of autoimmunity is likely to evolve as the rare and common genetic variants underlying autoimmune diseases are discovered and characterized, one by one. 
